Cardiac Amyloidosis Therapy: A Systematic Review
Cardiogenetics · 2021
DOI: 10.3390/cardiogenetics11010002 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cardiogenetics, 2021. Verfasst von Franco Iodice und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Heart involvement in Cardiac Amyloidosis (CA) results in a worsening of the prognosis in almost all patients with both light-chain (AL) and transthyretin amyloidosis (ATTR). The mainstream CA is a restrictive cardiomyopathy with hypertrophic phenotype at cardiac imaging that clinically leads to heart failure with preserved ejection fraction (HFpEF). An early diagnosis is essential to reduce cardiac damage and to improve the prognosis. Many therapies are available, but most of them have late benefits to cardiac function; for this reason, novel therapies are going to come soon.
Zitieren
APA
Iodice, F., Mauro, M. D., Migliaccio, M., Iannuzzi, A., Pacileo, R., Caiazza, M., & Esposito, A. (2021). Cardiac Amyloidosis Therapy: A Systematic Review. Cardiogenetics. https://doi.org/10.3390/cardiogenetics11010002
Vancouver
Iodice F, Mauro MD, Migliaccio M, Iannuzzi A, Pacileo R, Caiazza M, et al. Cardiac Amyloidosis Therapy: A Systematic Review. Cardiogenetics. 2021. doi:10.3390/cardiogenetics11010002
BibTeX
@article{Iodice2021,
author = {Iodice, Franco and Mauro, Marco Di and Migliaccio, Marco and Iannuzzi, Angela and Pacileo, Roberta and Caiazza, Martina and Esposito, Augusto},
title = {Cardiac Amyloidosis Therapy: A Systematic Review},
journal = {Cardiogenetics},
year = {2021},
doi = {10.3390/cardiogenetics11010002}
}
EUVIMED